PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer - LARVOL DELTA

Pneumococcal serotype distribution and diagnostic yield of serotype-specific urinary antigen detection in adults with CAP in Switzerland, 2016-2021: a prospective cohort study. (PubMed, BMC Infect Dis) - "The addition of ssUAD improved S. pneumoniae detection beyond standard methods. Although based on a small number of cases, the shift toward non-PCV13 serotypes underscores the potential benefit of higher-valency vaccines such as PCV20 and PCV21 for adult pneumococcal disease prevention in Switzerland."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Differences in influenza and pneumococcal vaccination coverage according to chronic respiratory diseases during the COVID-19 pandemic in France: a nationwide cohort study using the French national health data system. (PubMed, Respir Med Res) - "Primary pneumococcal sequence completion among French adults with CRDs was only 16% for pneumococcal vaccination over the 2013-2020 period, and seasonal influenza coverage was 56.8% for the 2020-2021 season, which is below the EU target of 75%. Older age and comorbidities were associated with higher uptake for influenza but not pneumococcal vaccination. In this high-risk population, post-pandemic monitoring of vaccination uptake is needed as well as strategies such as simplified vaccination schedules, expanded vaccinator roles, and systematic integration of vaccination into care pathways to improve protection."

Journal • Asthma • Bronchiectasis • Cardiovascular • Chronic Obstructive Pulmonary Disease • Cystic Fibrosis • Genetic Disorders • Hypertension • Immunology • Infectious Disease • Influenza • Interstitial Lung Disease • Lung Cancer • Non‐Cystic Fibrosis Bronchiectasis • Novel Coronavirus Disease • Oncology • Pneumococcal Infections • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Evaluation of the effect of serotype on pneumococcal conjugate vaccine-induced immunity: an exploratory analysis of the PREVENTING PNEUMO 2 trial. (PubMed, Lancet Microbe) - P4 | "PCV13 vaccination induced systemic humoral immune responses to both serotypes but they differed in magnitude, duration, and tissue distribution. The low mucosal immunity to Spn3 might contribute to reduced protection against Spn3 carriage acquisition."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

13-valent pneumococcal conjugate vaccine: 3-year impact on risk of major adverse cardiovascular events among Medicare beneficiaries in the United States (IDWeek 2026) - No abstract available

Adverse events • Medicare • Reimbursement • US reimbursement • Infectious Disease • Pneumococcal Infections

ACQUIVAS: Acquired Immunodeficiency in ANCA Associated Vasculitis (clinicaltrials.gov) - P2 | N=114 | Completed | Sponsor: Cambridge University Hospitals NHS Foundation Trust | Unknown status ➔ Completed

Trial completion • ANCA Vasculitis • Human Immunodeficiency Virus • Vasculitis

Residual Disparities in US Adults Hospitalized due to All-Cause Pneumonia Following Implementation of Childhood 13-Valent Pneumococcal Conjugate Vaccine in National Immunization Program. (PubMed, Open Forum Infect Dis) - "Despite reductions in inpatient all-cause pneumonia following pediatric PCV13 introduction, residual disparities persist for Black, at-risk/high-risk, and low- and middle-income adults. Strategies to reduce persistent disparities in disease burden among affected adults should be considered and implemented."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Residual Disparities in US Children Hospitalized Due to All-Cause Pneumonia Following Implementation of Childhood PCV13 in National Immunization Program. (PubMed, Vaccines (Basel)) - " Substantial reductions in rates of pediatric AC-hPNA were observed in the period subsequent to the introduction of routine PCV13, yet residual disparities persist among children with comorbidities and select racial and income groups. Targeted strategies are needed to address these gaps."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Kinetic profile and mucosal capsular polysaccharide IgG responses to serotype 3 pneumococcus in the adult oropharynx following an experimental human challenge. (PubMed, Front Microbiol) - "These data could help explain continued Spn3 population transmission despite widespread use of a Spn3-containing pneumococcal conjugate vaccine in the UK paediatric immunization programme. Within Spn3, clade Iα but not clade II increased mucosal IgG response following colonisation, which could help explain increasing transmission of clade II in the UK and higher transmission of this clade in mouse models."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years (clinicaltrials.gov) - P1 | N=230 | Completed | Sponsor: Reinovax Biologics Co., LTD | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

A Study to Evaluate 20vPnC in Healthy Chinese Infants (clinicaltrials.gov) - P3 | N=1250 | Recruiting | Sponsor: Pfizer

New P3 trial • Infectious Disease • Pneumococcal Infections

ZPY-CpG-Ch, a broad coverage vaccine against Streptococcus pneumoniae. (PubMed, Sci Adv) - "Existing licensed pneumococcal vaccines, including Prevnar-13 and its higher-valency successors, have played a major role in reducing invasive pneumococcal disease worldwide...We attribute this enhanced efficacy primarily to TH17 (T helper 7)-biased immune responses. Together, these findings highlight the promise of genome-guided, protein-based vaccines in overcoming the limitations of current serotype-based approaches and represent a meaningful step toward a truly universal pneumococcal vaccine."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (clinicaltrials.gov) - P3 | N=600 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Community-Acquired Pneumonia Incidence in Adults Aged 18 Years and Older in Goto City, Japan: A Prospective Population-Based Study. (PubMed, CHEST Pulm) - "Applying Goto's incidence and case fatality rate to the Japanese population, assuming PCV20 has the same vaccine efficacy and duration of protection as PCV13 and if licensed in Japan for the prevention of CAP, the inclusion of PCV20 in the national immunization program for adults ≥ 65 years of age could prevent 29,036 cases of CAP and 2,275 CAP-related deaths per year. Given the substantial burden of preventable pneumococcal disease, introduction of pneumococcal conjugate vaccines in Japanese adults may be of merit."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months (clinicaltrials.gov) - P2 | N=480 | Completed | Sponsor: Reinovax Biologics Co., LTD | Trial completion date: Aug 2027 ➔ Apr 2026 | Trial primary completion date: Jul 2027 ➔ Apr 2026 | Recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) - P4 | N=350 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Aug 2026 ➔ Nov 2036 | Trial primary completion date: Aug 2026 ➔ Nov 2036

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology • BCL2

Recombinant zoster vaccination reduces self-reported neurocognitive complaints in people with HIV (AIDS 2026) - "In PWH, RZV exhibited protective effects against SRNCs, consistent with findings in the general population and may thus be a useful intervention for supporting long-term neurological health."

Late-breaking abstract • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Herpes Zoster • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Pneumococcal Infections • Respiratory Diseases • Varicella Zoster • CD4

Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) - P4 | N=350 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | N=500 ➔ 350

Enrollment change • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology • BCL2

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - P1/2 | N=85 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Aug 2029 ➔ Feb 2031 | Trial primary completion date: Aug 2029 ➔ May 2030

Checkpoint inhibition • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan's pediatric National Immunization Program and impacts of a delayed implementation. (PubMed, Hum Vaccin Immunother) - "Delaying PCV20 introduction resulted in substantial losses, with a 1-y delay causing over 3,200 additional cases and exceeding NT$40 million in forgone savings, doubling with a 2-y delay. Implementing PCV20 in Taiwan's pediatric NIP is projected to improve health outcomes and reduce costs, while delays in implementation would lead to significantly avoidable losses compared with PCV13- or PCV15-based programs."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

SPLENEVAC-2: Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients. (clinicaltrials.gov) - P2 | N=39 | Completed | Sponsor: Assistance Publique - Hpitaux de Paris | Active, not recruiting ➔ Completed

Trial completion

Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model. (PubMed, Expert Rev Vaccines) - "Sensitivity and scenario results were consistent with the base-case. Pediatric PCV20 implementation in the UK could deliver substantial health gains while improving economic efficiency."

HEOR • Journal • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Pneumococcal Infections

Cost effectiveness and public health impact of PCV20 among adults in France. (PubMed, BMC Public Health) - "PCV20 is a cost-saving alternative to the PCV13 → PPV23 sequence for at-risk adults in France. Expanding recommendations to include all adults aged 65 years and over provides substantial public health gains and represents a highly cost-effective strategy."

HEOR • Journal • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Pneumococcal meningitis among hospitalised children after introduction of pneumococcal conjugate vaccine in India: a sentinel hospital surveillance (2019-2022). (PubMed, Lancet Reg Health Southeast Asia) - "In 2017 India introduced the 13-valent pneumococcal conjugate vaccine (PCV13; Prevenar 13®) in select high-burden sites and in 2021, transitioned to nationwide introduction of 10-valent PCV (PCV10-SII; PNEUMOSIL®). Continued surveillance is essential to monitor serotype distribution and pneumococcal meningitis patterns over time. Gates Foundation (OPP1188408) and the United Nations Development Programme (00101970)."

Journal • CNS Disorders • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

Safety and Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine According to Number and Timing of Primary Series Doses. (PubMed, Pediatr Infect Dis J) - "In this descriptive analysis of the 2 + 1 schedule, a 1-month delay in PCV20 priming to 3 and 5 months was associated with improved immune responses comparable to those of PCV13 at 2 and 4 months."

Journal • Infectious Disease • Pneumococcal Infections

Estimated pneumococcal disease burden in children due to serotypes covered by different pneumococcal conjugate vaccines in five Latin American countries. (PubMed, Front Pediatr) - "Despite the success of PCV10 and PCV13 in reducing pneumococcal disease in Latin America, a considerable clinical, economic, and societal burden remains due to serotypes included in higher-valent vaccines. Broader serotype coverage offered by PCV20 has the potential to address this unmet burden and further reduce the public health and economic impact of pneumococcal disease in young children across the region."

Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases